MétaCan
Menu
Back to cohort
Record W3180162850

Detection of tumor-related DNA methylation biomarkers in liquid biopsies from metastatic castration resistant prostate cancer patients to improve treatment decisions

2021· article· en· W3180162850 on OpenAlexaboutno aff
Madonna Peter, Misha Bilenky, Ruth Isserlin, Anthony M. Joshua, Aaron R. Hansen, Gary D. Bader, Neil Fleshner, Martin Hirst, Bharati Bapat

Bibliographic record

VenueJournal of Clinical Epigenetics · 2021
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsnot available
Fundersnot available
KeywordsEnzalutamideProstate cancerDNA methylationMedicineOncologyLiquid biopsyDifferentially methylated regionsInternal medicineAbiraterone acetateEpigenomicsCancerBioinformaticsBiologyAndrogen receptorGeneAndrogen deprivation therapyGenetics
DOInot available

Abstract

fetched live from OpenAlex

Background: Liquid biopsies are emerging as an important source of minimally invasive biomarkers, especially in metastatic castration resistant prostate cancer (mCRPC), where tumors are often inaccessible for biopsy based strategies. In particular, circulating cell free nucleic acids, such as cfDNA, can harbor tumor specific genomic and epigenomic changes. Tumor related DNA methylation markers are detectable in circulation of mCRPC patients; however, genome wide changes in the cfDNA methylome of mCPRC patients undergoing current androgen targeting therapies have not been extensively investigated. Methods/Results: In collaboration with the University Health Network Genitourinary Biobank (Toronto, Canada), we prospectively collected a cohort of mCRPC patients that received treatment with either enzalutamide or abiraterone acetate. Plasma cfDNA was isolated at baseline (prior to starting treatment), week-12 and clinical progression. As cfDNA methylation detection can be challenging due to low yield and quality, we optimized a protocol that involves methylated DNA immuno precipitation (MeDIP) followed by next generation sequencing (NGS). Overall, we are able to obtain good quality NGS data with high mappability to the genome as well as >5x coverage of 46-51% CpGs in the genome. We applied this MeDIP-seq protocol to cfDNA samples from 11 enzalutamide treated and 5 abiraterone treated patients that completed all study visits. We performed within patient analysis to identify differentially methylated regions (DMRs) associated with treatment and clinical progression. Overall, there were a number of DMRs identified through our established pipeline, with known mCRPC genes implicated, such as members of the HOX family of transcription factors and Wnt pathway members. Conclusions: Overall, we are able to detect methylation signals from low yields of cfDNA and potentially tumor specific methylation markers. We are currently performing pathway analysis and correlation with clinical parameters. Validation of these methylation markers in mCRPC could further shed light on underlying disease mechanisms and novel biomarkers. Biography Madonna R Peter is currently a PhD student at the University of Toronto, Department of Laboratory Medicine & Pathobiology and under the Supervision of Dr. Bharati Bapat (Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada). Previously, she completed her MSc in the Department of Immunology (University of Toronto)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.357
Threshold uncertainty score0.433

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.070
GPT teacher head0.417
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical EpigeneticsSame topicProstate Cancer Treatment and ResearchFrench-language works237,207